Mohammad Abdollahi

Featured in: Favicon

sagepub.com Favicon

tandfonline.com Favicon

thelancet.com Favicon

hindawi.com Favicon

journals.plos.org

Articles

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 - The Lancet

May 16, 2024 | thelancet.com | S List |Michael Brauer |Gregory A. Roth |Mohammad Abdollahi

SummaryUnderstanding the health consequences associated with exposure to risk factors is necessary to inform public health policy and practice.
Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs

Feb 23, 2024 | tandfonline.com | Mohammad Abdollahi

References Corsetti M, Whorwell P. Novel pharmacological therapies for irritable bowel syndrome. Expert review of gastroenterology & hepatology. Exp Rev Gastroenterol Hepatol. 2016;10(7):807–815. doi: 10.1586/17474124.2016.1158099 View PubMed Web of Science ®Google Scholar Deiana S, Gabbani T, Bagnoli S, et al. Emerging drug for diarrhea predominant irritable bowel syndrome. Expert Opin Emerg Drugs. 2015;20(2):247–261.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →